Oxaliplatin combined with vinorelbine in drug resistant non-small-cell lung cancer
- VernacularTitle:奥沙利铂联合长春瑞滨治疗耐药非小细胞肺癌
- Author:
Mafei KANG
;
Hejun JIANG
;
Mingjie TANG
- Publication Type:Journal Article
- Keywords:
lung neoplasm;
chemotherapy;
oxaliplatin;
vinorelbine
- From:
China Oncology
2001;0(02):-
- CountryChina
- Language:Chinese
-
Abstract:
Purpose: To observe the efficacy and the side effects of oxaliplatin( OXA) in combination with vinorelbine (VRB) in the treatment of drug resistant non-small-cell lung cancer( NSCLC) . Methodii: Thirty-five patients with drug resistant lung cancer were treated by OXA + VRB. OXA 100 mg/m2, VRB 25 mg/m , on d 1, which were given by bronchial arteries injection, and VRB 25mg/m2 was given by venous injection on d 8. One cycle was given every 3 weeks and total six cycles was given. Results: There was 1 patient who showed completed remission( CR), 14 patients showed partial remission( PR), 13 patients showed stable disease( SD) and 7 patients showed progress disease( PD) after the sixth cycle. The response rate was 42. 9%. The major toxicities were peripheral sensory neuropathy and leukopenia. Conclusions: The regimen of OXA plus VRB is effective on drug resistant and advanced NSCLC and the side effects are tolerable. There is higher response rate and lower neurotoxicity when the medicines are given by arterial injection than by venous injection.
